External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma

Cancer

Volumn 112, Issue 7, 2008, Pages 1471-1479

  Hoffmann, Nathan E ^a   Sheinin, Yuri ^a   Lohse, Christine M ^a   Parker, Alexander S ^b   Leibovich, Bradley C ^a   Jiang, Zhong ^c   Kwon, Eugene D ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; Cancer progression; IMP3; Insulin like growth factor; Kidney cancer; mRNA binding protein

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE COURSE; DISEASE MARKER; EXTERNAL VALIDITY; FEMALE; HAZARD ASSESSMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SARCOMA; TISSUE SECTION; TUMOR NECROSIS;

AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MALE; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RNA-BINDING PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 41149145266     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23296     Document Type: Article

References (21)

1. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556-564.
2. Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004;171:2461-2466.
3. Krambeck AE, Dong H, Thompson RH, et al. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1749-1756.
4. Byun SS, Yeo WG, Lee SE, et al. Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology. 2007;69:34-37.
5. Krambeck AE, Thompson RH, Dong H, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006;103:10391-10396.
6. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174-17179.
7. Tollefson MK, Thompson RH, Sheinin Y, et al. KI-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer. 2007;110:783-790.
8. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19:453-473.
9. Bleeker SE, Moll HA, Steyerberg EW, et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol. 2003;56:826-832.
10. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med. 1999;130:515-524.
11. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer Press; 2002.
12. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131-133.
13. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
14. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663-1671.
15. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst. 2007;99:236-243.
16. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-1184.
17. Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl. 2001;234:93-99.
18. Parker A, Cheville JC, Lohse C, et al. Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol. 2003;170:420-424.
19. Holt RI, Teale JD, Jones JS, et al. Gene expression and serum levels of insulin-like growth factors (IGFs) and IGF-binding proteins in a case of non-islet cell tumour hypoglycaemia. Growth Horm IGF Res. 1998;8:447-454.
20. Fernando HS, Hawkyard SJ, Poon P, et al. Renal cell carcinoma with non-islet cell tumor hypoglycemia. Int J Urol. 2006;13:985-986.
21. Schips L, Zigeuner R, Ratschek M, et al. Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol. 2004;122:931-937.